5HT(1A) receptor antagonists enhance the functional activity of fluoxetine in a mouse model of feeding

Brain Research

Volumn 781, Issue 1-2, 1998, Pages 121-128

  Li, Dominic L ^a   Simmons, Rosa M A ^a   Iyengar, Smriti ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5HT(1A) receptor; Feeding; Fluoxetine; LY206130; Pindolol

Indexed keywords

5 HYDROXYTRYPTOPHAN; FLUOXETINE; LY 206130; PINDOLOL; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; CYCLOHEXYLAMINE DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; APPETITE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EATING DISORDER; FEEDING; FOOD INTAKE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MILK; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRAINING; ANIMAL; DRINKING BEHAVIOR; DRUG EFFECT; DRUG POTENTIATION; FEEDING BEHAVIOR; MOUSE STRAIN;

ANIMALS; CYCLOHEXYLAMINES; DRINKING BEHAVIOR; DRUG SYNERGISM; FEEDING BEHAVIOR; FLUOXETINE; MALE; MICE; MICE, INBRED STRAINS; PINDOLOL; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032545666     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01221-3     Document Type: Article

References (36)

1. Advokat C., Kutlesic V. Pharmacotherapy of the eating disorders: a commentary. Neurosci. Biobehav. Rev. 19:1995;59-66.
2. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin re-uptake inhibitors. Arch. Gen. Psych. 51:1994;248-251.
3. 2c receptors, respectively. Neuropsychopharmacology. 13:1995;1-8.
4. Blier P., Bergeron R. Effectiveness of pindolol with selected anti-depressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
5. Caccia S., Cappi M., Fracasso C., Sarattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology. 100:1990;509-514.
6. Coughenour L.L., McLean J.R., Parker R.B. A new device for the rapid measurement of impaired motor function in mice. Pharmacol. Biochem. Behav. 6:1977;351-353.
7. Curzon G. Effects of tryptophan and of 5-hydroxytryptamine receptor subtype agonists on feeding. Adv. Exp. Med. Biol. 294:1991;377-388.
8. 1A receptors. Neurochem. Res. 21(5):1996;557-562.
9. Engleman E.A., Robertson D.W., Thompson D.C., Perry K.W., Wong D.T. Antagonism of serotonin 5-HT1 receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J. Neurochem. 66:1996;599-603.
10. Feldman R.S., Smith W.C. Chlordiazepoxide-fluoxetine interaction on food intake in free feeding rats. Pharmacol. Biochem. Behav. 8:1978;749-752.
11. Fuller R.W., Owen J.E. Suppression of milk drinking by the combination of fluoxetine and L-5-hydroxytrytophan in rats. Res. Comm. Chem. Path. Pharm. 34(1):1981;137-140.
12. Fuller R.W., Perry K.W., Hemrick-Luecke S.K., Engleman E. Serum corticosterone increases reflect enhanced uptake inhibitor-induced elevation of extracellular 5-hydroxytryptamine in rat hypothalamus. J. Pharm. Pharmacol. 48:1996;68-70.
13. 1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs - recent findings from in vivo microdialysis studies. Fund. Clin. Pharmacol. 10:1996;16-27.
14. Goldstein D.J., Rampey A.H. Jr., Enas G.G., Potvin J.H., Fuldzinski L.A., Levine L.R. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int. J. Obes. Relat. Metab. Disord. 18:1994;129-135.
15. Goldstein D.J., Rampey A.H. Jr., Roback P.J., Wilson M.G., Hamilton S.H., Sayler M.E., Tollefson G.D. Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success. Obesity Res. 3:1995;481S-490S.
16. Grignaschi G., Samanin R. Role of serotonin and catecholamines in brain in the feeding suppressant effect of fluoxetine. Neuropharmacology. 31:1992;445-449.
17. 2a receptors in the paraventricular hypothalamus attenuates neuropeptide Y-induced hyperphagia through activation of corticotropin releasing factor. Brain Res. 708:1996;173-176.
18. Hutson P.H., Dourish C.T., Curzon G. Neurochemical and behavioural evidence for mediation of the hyperphagic action of 8-OH-DPAT by 5-HT cell body autoreceptors. Eur. J. Pharmacol. 129:1986;347-352.
19. 1A receptors. Eur. J. Pharmacol. 150:1988;361-366.
20. 1A autoreceptors in the action of selective serotonin re-uptake inhibitors. Eur. J. Pharmacol. 260:1994;251-255.
21. Jimerson D.C., Lesem M.D., Kaye W.H., Hegg A.P., Brewerton T.D. Eating disorders and depression: is there a serotonin connection? Biol. Pysch. 28:1991;443-454.
22. Kim S.H., Wurtman R.J. Selective effects of CGS10686B, DL-fenfluramine or fluoxetine on nutrient selection. Physiol. Behav. 42:1988;319-322.
23. Lam R.W., Gorman C.P., Michalon M., Steiner M., Levitt A.J., Corral M.R., Watson G.D., Morehouse R.L., Tam W., Joffy R.T. Multicenter placebo-controlled study of fluoxetine in seasonal affective disorder. Am. J. Psych. 152:1995;1765-1770.
24. Levine L.R., Rosenblatt S., Bosomworth J. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int. J. Obes. 11:1987;185-190.
25. Levine L.R., Enas G.G., Thompson W.L., Byyny R.L., Dauer A.D., Kirby R.W., Kreindler T.G., Levy B., Lucas C.P., McIlwain H.H.et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int. J. Obes. 13:1989;635-645.
26. 1A agonist. J. Pharmacol. Exp. Ther. 279:1996;1035-1042.
27. Luo S.Q., Li E.T. Food intake and selection pattern of rats treated with dexfenfluramine, fluoxetine and RU24969. Brain Res. Bull. 24:1990;729-733.
28. Noach E.L. Appetite regulation by serotoninergic mechanisms and effects of D-fenfluramine. Neth. J. Med. 45:1994;123-133.
29. O'Kane M., Wiles P.G., Wales J.K. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet. Med. 11:1994;105-110.
30. Perry K.W., Fuller R.W. Extracellular 5-hydroxytryptamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan. J. Pharm. Pharmacol. 45:1993;759-761.
31. Rutter J.J., Auerbach S.B. Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J. Pharmacol. Exp. Ther. 265:1993;1319-1324.
32. Tollefson G.D., Rampey A.H. Jr., Potvin J.H., Jenike M.A., Rush A.J., Dominguez R.A., Koran L.M., Shear M.K., Goodman W., Genduso L.A. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psych. 51:1994;559-567.
33. D.T., Wong, F.P. Bymaster, Development of anti-depressant drugs, Fluoxetine (Prozac) and other selective serotonin uptake inhibitors, in: L. Tang, S. Tang (Eds.), Neurochemistry in Clinical Application, Plenum, New York, 1995, pp. 77-95.
34. Wong D.T., Bymaster F.P., Horng J.S., Molloy B.B. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. J. Pharmacol. Exp. Ther. 193:1975;804-811.
35. 1A receptor. Soc. Neurosci. 20:1994;1542. Abstract.
36. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: 20 years since its first publication. Life Sci. 57:1995;411-441.